Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to seek research applications that pilot test approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care. Research applications should be developed to pilot test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal is that, if the pilot study shows promising results, the data from the R34 will be used to support a full-scale trial focused on improving routine healthcare practice and informing healthcare policy for the prevention or management of diabetes and obesity. Therefore, interventions must be integrated into the existing healthcare structure and/or processes. The healthcare setting may not be used solely as a venue for recruitment.

This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life.

The American Diabetes Association is accepting applications for its Innovative Basic Science Awards. Through the annual research program, the association awards grants of up to $115,000 over three years in support of creative and innovative projects that hold significant promise for advancing the prevention, cure, or treatment of diabetes. Priority is given to high-risk projects with the potential to generate high-impact results; projects that extend existing knowledge into a new area or application; projects that utilize novel technological or cross-disciplinary approaches; and/or projects that may not be sufficiently developed for traditional funding sources (e.g., NIH R01). Applicant must hold a PhD, MD, PharmD, DO, or DPM degree (or, for other health professionals, the equivalent doctoral-level health- or science-related degree) and possess the necessary skills and training to carry out the proposed work. At the time of application, applicants must hold a full-time independent faculty position or the equivalent at a university-affiliated research institution or other nonprofit research institution. (Awards are limited to institutions in the United States and U.S. possessions.) See the ADA website for complete program guidelines and application instructions.

Once established, type 1 diabetes (T1D) requires daily insulin administration and episodes of hyperglycemia and hypoglycemia are common. As a result, patients with T1D without adequate control may suffer devastating acute complications such as life-threatening hypoglycemia and ketoacidosis and long term complications including accelerated cardiac and peripheral vascular diseases, nephropathy, retinopathy, neuropathy, amputation and premature death. Studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have shown that long term microvascular and macrovascular complications can be reduced through tight blood glucose control. However, the increased risk of hypoglycemia that is associated with tight control and the limitations of current glucose control technologies make tight control difficult to achieve. Thus, there is a need for tools to help more people with T1D to safely achieve and sustain tight blood glucose control and reduce burden of care.

The State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity and Associated Risk Factors and Promote School Health - FOA - DP13-1305 outlines an approach to preventing and reducing the risk factors associated with childhood and adult obesity, diabetes, heart disease, and stroke; it also addresses management of these chronic diseases. The activities and strategies outlined in this FOA (see logic model on page 7) are organized by the four chronic disease prevention and health promotion domains: 1) Epidemiology and surveillance; 2) Environmental approaches that promote health and support and reinforce healthful behaviors; 3) Health system interventions to improve the effective delivery and use of clinical and other preventive services; and 4) Community-clinical linkages to support cardiovascular disease (CVD) and diabetes prevention and control efforts and the management of chronic diseases.

The goal of this Funding Opportunity Announcement (FOA) is to support research that will identify barriers and facilitators to good diabetes self management in adults with type 1 diabetes. The results from this research should inform future intervention research in adults with type 1 diabetes.

This Funding Opportunity Announcement (FOA) encourages NIH Research Project Grants (R01) to test practical, sustainable, and cost efficient adaptations of efficacious strategies or approaches to prevent and treat diabetes and/or obesity. Research focused on the prevention or reversal of obesity, prevention of type 2 diabetes, improved care of type 1 and type 2 diabetes, or the prevention or delay of the complications of these conditions is encouraged. The approaches tested should have the potential for wide dissemination and implementation outside of an academic setting such as in routine clinical practice or communities at risk.

Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia.  NIDDK has long supported this area of research, especially through small business projects, and this support has contributed substantially to the development of new devices that are increasingly used in clinical practice.  Nonetheless, the approved devices and current technologies still have significant limitations, and it is important to put renewed emphasis on the creation of the next generation of devices that will further the goals of relieving patients of the burden of diabetes self-management and achieving daily euglycemia to prevent acute and chronic complications. However, given the pace of technical progress in this field and the substantial room for improvement in reliability, accuracy, and patient burden of current devices, NIDDK considers it important to continue supporting research in this field. This FOA is intended to support cutting edge research conducted by small business leading to the development of innovative technologies that may advance progress toward an integrated, long term, wearable/implantable, glucose regulated open and closed loop insulin/pancreatic hormone delivery systems.  This announcement has two main purposes: a) promote technical innovation and b) pre-clinical testing of single or combined components of open and closed loop systems

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).

to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions

This Limited Competition Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the six current Clinical Centers (CCs) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study of Type 1 Diabetes (T1D) etiology. The TEDDY study involves the rigorous investigation of TEDDY subjects, collecting data and samples, for the identification of infectious agents, dietary factors, or other environmental factors associated with onset of T1D and/or T1D associated autoimmune markers. The six current CCs have been involved in study design and data and biosample acquisition since the inception of the TEDDY consortium. The CCs have recruited participants and followed the subjects over the past 15 years. In addition, the CCs have established effective and proficient collaborations with other components of TEDDY to carry out the studies to meet the objectives of this program.

The purpose of this Research Demonstration and Disseminations Projects (R18) Funding Opportunity Announcement (FOA) is to support research to evaluate large scale policies or programs related to healthcare delivery that are expected to influence diabetes prevention and care. This FOA is not intended to support the initiation and delivery of new policies or programs. Research support is for the evaluation of the effectiveness of healthcare programs and/or policies implemented independent of NIH grant funding. The goal is to support research that meaningfully informs clinical practice and health policy related to prevention or management of diabetes.

The purpose of this Planning Grant (R34) is to support research to develop and pilot test approaches to improve diabetes treatment and prevention in existing healthcare settings. Applications should pilot test practical and potentially sustainable strategies, delivered in routine clinical care settings, to improve processes of care and health outcomes of individuals who are at risk for or have diabetes. The goal is that, if the pilot study shows promise, the data from the R34 will be used to support a full scale trial that could improve routine clinical practice and inform policy in representative healthcare settings.

The purpose of this Research Demonstration and Dissemination Projects (R18) Funding Opportunity Announcement (FOA) is to support research to test approaches to improve diabetes treatment and prevention in existing healthcare settings. Applications are sought that test practical and potentially sustainable strategies, delivered in routine clinical care settings, to improve processes of care and health outcomes of individuals who are at risk for or have diabetes. The goal is that the research results will improve routine clinical practice and inform policy in representative healthcare settings.

The purpose of this Research Demonstration and Dissemination Projects (R18) Funding Opportunity Announcement (FOA) is to encourage research applications to test approaches to improve diabetes and obesity prevention and/or treatment in routine healthcare settings.  Research applications should be designed to test practical and potentially sustainable strategies to improve processes of care and health outcomes for individuals who are overweight or obese or at risk for becoming overweight or obese and/or at risk for or have type 1 or type 2 diabetes. The goal of the research is to obtain results that will improve routine healthcare practice and inform healthcare policy for the prevention or management of these conditions.

This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the web portal and underlying, curated knowledge base; as well as to become the flagship resource encompassing the myriad types of data and information that provides an understanding of the biological heterogeneity in patients with T2D and its complications. In its next five-year period, the AMP T2D KP will be expected to expand the KPs data sets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base. To support the conduct of these studies, the AMP T2D KP will coordinate, support, and work with companion Functional Genomic Project awardees (RFA-DK-19-012) to form a Consortium. The AMP T2D KP will also oversee an opportunity pool of funds to solicit collaborative projects to accomplish the objectives of the Consortium.

Through this annual research program, the association awards grants of up to $115,000 over three years in support of innovative projects that hold significant promise for advancing the prevention, cure, or treatment of diabetes. Priority is given to high-risk projects with the potential to generate high-impact results; that extend existing knowledge into a new area or application and that utilize novel technological or cross-disciplinary approaches; and/or that may not be sufficiently developed for traditional funding sources

The purpose of this Funding Opportunity Announcement (FOA) is to elucidate the etiology and pathogenesis of the neurocognitive complications associated with type 2 diabetes (T2D) with the ultimate goal of informing future strategies to mitigate the risk of these complications. Applications should propose expansions of ongoing human studies of well characterized T2D cohorts or cohorts comparing T2D with non-diabetic populations.  Such expansions might include the addition of comprehensive neurocognitive measures (e.g., cognitive testing, neuroimaging, and biomarkers), clinical measures (e.g., insulin resistance, HbA1c), and/or collection of data on other risk factors (e.g., diet, obesity, micro- and macro-vascular disease, inflammation). It must be clearly explained how the collection of additional data will contribute to elucidation of the basis of neurocognitive sequelae of T2D.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) seeks research to improve understanding of the causes of high priority diseases in the United States and to develop and test more effective interventions for reducing/eliminating health disparities. Research is encouraged in the following high priority diseases within the scientific mission areas of the NIDDK: diabetes, obesity, nutrition-related disorders, hepatitis C, gallbladder disease, H. Pylori infection, sickle cell disease, kidney diseases, urologic diseases, hematologic diseases, metabolic, gastrointestinal, hepatic, and renal complications from infection with HIV.